53 results about "Alternative medicine" patented technology

A device for treating diseases and chronic ailments of the human body by inducing powerful, short duration magnetic pulses in close proximity to a region of the body. The device comprises an electromagnetic coil or inductor energized by an electric circuit and a power source, pulsed between 1 and 25 pulses per second for therapeutic means and use as an alternative medical treatment. The device comprises an electric circuit that transmits pulsating current to an induction coil placed within a handheld stylus device for introducing a high energy, pulsed magnetic field to target locations on the body. The stylus is placed against the human body and introduces the pulsating magnetic field into and through body tissue, bone and the bloodstream. The stylus is completely noninvasive and provides a means to direct magnetic energy to a specific part of the body. The device is an advancement in the art, and one that provides increased magnetic energy and pulse frequency without the use of Xenon flash tubes that consume large quantities of power.

The invention provides a lactobacillus plantarum ZJ316 which is separated from excrement of infants and anti-bacterial peptide which is produced by the fermentation of the lactobacillus plantarum ZJ316, namely plantaricin ZJ316, and preparation and application thereof; the plantaricin ZJ316 is a novel lactobacillus anti-bacterial peptide with high efficiency and small molecular; the anti-bacterial peptide has bacteriostatic action of broad spectrum; due to small molecular weight, a lipid bilayer is hard to be crossed so as to form a complex body with small holes to be different from the action mode of nisin; but the anti-bacterial peptide also has sterilizing capacity with high efficiency, is a lantibiotic anti-bacterial peptide with superhigh application and development potential and can be applied to preparing the alternative medicine of feed additives, food preservatives and antibiotic, etc.

An exemplary embodiment providing one or more improvements includes feeding animals with probiotic microbes encapsulated in a mixture of xanthan gum and chitosan, or in gelatin, specifically Pediococcus acidilactici and Saccharomyces boulardii. Such encapsulation protects the viability of the probiotic microbes against unfavorable temperatures. An exemplary embodiment providing one or more improvements includes methods of using viable probiotics in therapy of birds and mammals infected with infectious diseases. Probiotics acted as adjuvants in stimulating antibody reaction and stimulated a cellular immunity response. In particular, probiotics were shown to reduce the number of viable oocytes from fecal samples, stimulate antibody production, and stimulate of proliferation of splenocytes in chickens infected with Elimeria. In addition, probiotics were shown to relieve symptoms of parvovirus infection in dogs.

An elongate device (19), arcuate in cross-section, for placement around a vessel (4), comprises an essentially non-porous outer layer and a biodegradable inner layer. An alternative device comprises a tubular portion (3) for placement around a graft and a portion (2), arcuate in cross-section that can straddle a native vessel, at the site of an end-to-side anastomosis.

The invention belongs to the field of chemistry and pharmacy, and particularly relates to clinafloxacin amino derivatives and application thereof. The clinafloxacin amino derivatives are the compounds shown in the formula 1 (R is -SO2R1 or -COR2) or pharmaceutically acceptable salts thereof. The antibacterial activity of the derivatives is close to or superior to that of clinafloxacin, the toxicity of the derivatives is lower than that of clinafloxacin, and the solubility and the stability of the solution of the derivatives are superior to those of clinafloxacin. The derivatives can be used for preparing antibacterial medicines, thereby providing more efficient and safe alternative medicines for clinical treatment of infectious diseases and satisfying the demands for clinical treatment in many aspects.

The invention relates to an in-situ gel preparation of potassium dehydroandrographolide succinate and a preparation method thereof. The preparation is prepared from potassium dehydroandrographolide succinate (dehydration andrographolide butanedioic acid ester single sylvite half), in-site gel substrates recognized in the field, and other pharmaceutic adjuvants necessary for other pharmacy by using water as a solvent. In-situ gel of potassium dehydroandrographolide succinate is liquid freely moving outside a body, and forms semisolid gel after patients take the gel. The invention has the advantages of definite effect, stable performance, simple preparation, convenient administration, strong compliance for patients, no toxic and side effect, no untoward effect, high bioavailability, and on the like. The in-situ gel preparation has good antipyretic and antiinflammatory action, can be used for clinically treating viral respiratory tract infection and viral pneumonia, can be used as alternative medicine for potassium dehydroandrographolide succinate injection, and is particularly suitable for infants and patients who have trouble in taking medicine.

The invention discloses application of pithecellobium clypearia extracts to preparation of multi-drug resistant acinetobacter baumannii medicine. The pithecellobium clypearia extracts are prepared through the method includes the steps that pithecellobium clypearia coarse powder is extracted with water or an ethyl alcohol solution, the obtained extraction liquid is extracted with ethyl acetate, and the obtained extracts are target products. The antibacterial function of the pithecellobium clypearia extracts to multi-drug resistant acinetobacter baumannii and the sensitivity enhancing function of the pithecellobium clypearia extracts to similar antibiotics are disclosed for the first time. Tests prove that the pithecellobium clypearia extracts and imipenem or tetracycline or polymyxin B or ceftazidime or levofloxacin take effect together, and the use amount of antibiotics can be reduced by 50-87% compared with the mode that only the pithecellobium clypearia extracts are used. The pithecellobium clypearia extracts can serve as natural multi-drug resistant acinetobacter baumannii medicine or an antibiotic sensitivity-enhancing agent, and is applied to treatment of diseases caused by acinetobacter baumannii. A new means and alternative medicine are provided for solving the drug resistance problem of similar antibiotics.

The invention relates to a quinolone imidazole compound as well as a preparation method and application thereof, and belongs to the technical field of chemical synthesis. The quinolone imidazole compound is shown as general formulas I-IV. The compound has certain inhibition activity on one or several kinds of materials in gram positive bacteria, gram-negative bacteria and fungi, and can be used for preparing anti-bacterial and/or anti-fungal medicine, so that the compound has the opportunity to provide more safe efficient and diversified alternative medicine for clinic antimicrobial treatment;the clinic treatment problems of daily serious drug resistance, stubborn pathogenic microbes, newly occurring harmful microbes and the like can be favorably solved. The preparation raw materials aresimple; the price is low; the obtaining is easy; the synthesis path is short; important significance is realized in aspect of infection resistance. The formulas are shown in the description.

An assay method to identify agents that will reduce the inflammation associated with many diseases, providing a method to determine compliance of patients to clinical protocols. The fundamental tool of the inventive method is luminescence. Genetically modified cells are used to express a complex revealing the potential of certain compounds to prevent or reduce adverse effects. More specifically the invention is a method for the determination of inhibition of a chemical compound comprising: culturing genetically modified cells which express an indicator-luminescent complex; placing said complex in the presence of an agent that essentially totally degrades said complex; measuring the luminescence of the resulting reaction; collecting a sample from a mammal consuming a complementary and alternative medicine (CAM); placing said sample in the presence of said complex; and comparing the level of luminescence from step (c) with the luminescence from step (e) to determine the inhibition of said chemical compound.

The invention provides a hypolipidemic compound demethyleneberberine. The demethyleneberberine is derived from a main in-vivo metabolite of natural medicine berberine. The researches on model animals with hyperlipidemia find that the demethyleneberberine has good drug effects of reducing cholesterol, triglyceride, low density lipoprotein (LDL) and the like, and has no obvious side effects for 6 weeks of continuous medication. The discovery can lead to discovery of a new hypolipidemic drug, and provides another alternative medicine for clinic treatment of hyperlipidemia, lipid metabolism disorder and high fat and obese patients and related people wanting to lose weight.

The invention provides an AI model automatic generation method based on computational graph evolution. The method mainly comprises the following steps: presetting data; Utilizing a genetic algorithm operator to generate a first-generation calculation graph model and calculating model performance according to a calculation graph structure; removing the invalid model and the repeated model, and reserving the remaining models as alternative models as seeds of the next generation; Selecting a plurality of optimal models; The alternative model generates a calculation graph new model by using a genetic algorithm operator; judging whether the new calculation graph model generated in the last step is generated or not; storing the new model as a new generation of computational graph model, and judging whether the new model meets preset data and evolutionary ending conditions or not; and summarizing evolutionary calculation results, and selecting an optimal model. According to the invention, machine learning and deep learning can be carried out simultaneously. The repeated calculation frequency of the same model is avoided, and the model design efficiency is improved; Jumping out of local optimum; Declining of the performance of the search network is prevented. The evaluation can be directly carried out without training through actual data.

The invention relates to a tetrahydrobenzofuran-4-ketoximetriazole medicine. The medicine is a cis-isomeride of tetrahydrobenzofuran-4-ketoximetriazole medicine, and also comprises pharmaceutically acceptable salts and derivatives of the tetrahydrobenzofuran-4-ketoximetriazole medicine. A preparation method of the tetrahydrobenzofuran-4-ketoximetriazole medicine comprises the following steps: preparing 3,6,6-trimethyl-6,7-dihydrobenzofuran-4(5H)-one (intermediate 1) and nitrine (intermediate 2), carrying out a condensation reaction to convert the intermediate 1 into cis-oxime (intermediate 3), separating, purifying, alkylating to obtain propargyl oxime ether (intermediate 4), and carrying out a copper catalyzed cycloaddition reaction on the intermediate 4 and the nitrine (intermediate 2) to synthesize 1,2,3-triazole substituted furocyclohexanone oxime and a derivative thereof. The above compounds have dual curative effects of antiulcer and stomach cancer resistance, and can be used in stomach cancer treatment as alternative medicines.

A method, system and computer-usable medium for performing a meal kit personalization operation, comprising: receiving recipe purchase history information for a plurality of customers; associating the recipe purchase history information with a plurality of input recipes; identifying a plurality of input recipes for use for a particular time period; identifying elements of the input recipes that limit appeal of each of the plurality of input recipes for the particular time period, the elements being identified using purchase predictor information relating to the elements; generating alternative recipes based upon the input recipes; and selecting a predefined number of these input recipes and alternative recipes for presentation to a particular user.

This invention provides information regarding the methods and procedures for manufacturing a new medical device, Health recovery chip kit. It also describes the methods and steps for using this kit to treat the chronic, but non-contagious diseases. The treatment by this kit is safe, more effective, non-invasive and easy to use over other alternative treatments because it does not involve needles, medication, electricity and radiation.

The invention discloses application of remdesivir in preparation of a medicine for inhibiting cardiotoxicity of anti-tumor medicines. The invention confirms significant potential of the retegravir asa medicine for inhibiting the cardiotoxicity of anti-tumor medicines, discloses good curative effects of the retegravir on the cardiotoxicity caused by the anti-tumor medicines for the first time, provides an effective novel potential alternative medicine for treating the cardiotoxicity of the anti-tumor medicines, expands indications of the retegravir, and greatly improves application potential and market prospect of the retegravir.

A medical information system informs prescribers of medically related drug information when preparing a prescription. The point of prescribing messaging system can assist physicians in selecting alternative medications when prescribing medication for patients. The system may include a point of prescription application configured to access and display messages concerning alternative suggested medications of different sponsors in response to an associated selected medication to inform prescribers of the alternative suggested medication for presenting the prescriber with the option of generating an electronic prescription with the alternative suggested medication. A data structure maintained by the system containing associations between a selected trigger medication and a target alternative suggested medication may optionally include additional conditions that control the display of messages such as the gender, age, and/or diagnosis of the patient, the date of the prescription, and/or the region in which the prescription is being made.

The invention provides an ECG signal detection method, a detection device, computer equipment and a storage medium. The detection method comprises the following steps: inputting and training a first ECG signal of a known signal rhythm type in a convolutional neural network so as to obtain corresponding training parameters, and using the convolutional neural network from which the training parameters are obtained as an ECG signal detection model; and inputting and computing a second to-be-detected ECG signal in the ECG signal detection model, and outputting and obtaining a signal rhythm type ofthe second ECG signal. The ECG signal detection model, which undergoes training, can replace medical specialists to complete full automatic detection of signal rhythm types in the ECG signals of a patient, so that a great amount of human and material costs can be saved; and meanwhile, the accuracy of detecting the signal rhythm types in the ECG signals can reach, and even exceed, that of the specialists.

The invention provides a cascading failure search comprehensive assessment method based on a probability index and a severity index, by analysis of an operating state of a power grid after each class of failure, a probability index and a severity index of a failure occurring in a next-class alternative line are obtained, and a cascading failure comprehensive risk index of the alternative line is obtained through classified integration. The method is convenient, simple and efficient, and can provide a basis for judging weak links of a system, and making a prevention and control strategy for lowering cascading failure risks.